Xenetic Biosciences (XBIO) investor relations material

Executive summary

• Focused on advancing DNase technology for oncology, with ongoing preclinical and clinical development efforts targeting hard-to-treat cancers.

• Expanded strategic partnership with The Scripps Research Institute to advance DNase I and CAR T-cell therapy program.

• Entered clinical study agreements and commenced patient dosing in exploratory studies for DNase I combinations in lymphoma and pancreatic cancer.

• Royalty revenue from legacy PolyXen technology continues, but no commercialized products to date.

• Significant resources remain committed to research and development, with a single operating segment structure.

Financial highlights

• Revenue for Q2 2025 was $0.59M, down 18.8% year-over-year due to lower royalty revenue from Takeda.

• Net loss for Q2 2025 was $0.69M, a 45.9% improvement from Q2 2024.

• Operating expenses for Q2 2025 decreased 36.3% year-over-year, mainly due to lower R&D and G&A costs.

• Cash at June 30, 2025 was $4.8M, down from $6.2M at December 31, 2024.

• For the six months ended June 30, 2025, revenue was $1.18M (down 4.4% year-over-year), and net loss was $1.59M (improved 35.5% year-over-year).

Outlook and guidance

• Existing resources expected to fund operations for at least 12 months from the reporting date.

• Advancing DNase-based oncology program toward Phase 1 clinical development for pancreatic carcinoma and other solid tumors.

• Additional capital will be needed long-term to pursue business initiatives; access to capital markets is subject to volatility and external factors.

• Building momentum across partnerships and development fronts, aiming for IND and Phase 1 trial.